JMP Securities analyst Silvan Tuerkcan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Market Outperform rating and announces Price Target of $7.
JMP Securities Initiates Coverage On Elevation Oncology With Market Outperform Rating, Announces Price Target of $7
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.